BioPontis Discusses New Impact Investing Finance Model in Leading French Life Sciences Trade Publication

FOR RELEASE: 2017 26 October

BioPontis Discusses New Impact Investing Finance Model in Leading French Life Sciences Trade Publication

Brussels, Belgium and Raleigh, NC USA

BioPontis Alliance for Rare Diseases Board Chair, Dr. Erik Tambuyzer is featured in a recent edition of the leading French life sciences trade publication ‘Biotech Finances’ (2017 23 OCT) in their Big Picture section (pp 6-7). Erik explains what sets BioPontis Alliance apart from other nonprofits in the area of rare diseases as well as its progress to add impact investment as part of its financing model. Readers can find the article here; it is in the French language.


About BioPontis Alliance for Rare Diseases

BioPontis Alliance for Rare Diseases is a 501c(3) public charity in the US (North Carolina) and a foundation of public utility (fup/son) in Belgium (Brussels). Managed by an international Board and executive team, BioPontis partners with patient organizations and clinical researchers to bridge the gap between promising science and new medicines. BioPontis Alliance for Rare Diseases is being established as a global non-profit, inviting corporate, private and foundation philanthropic support. More information, including how contributions to support our programs and mission can be made, at http://biopontisalliance.org.

 

Contacts:

Erik Tambuyzer, Chairperson BioPontis Alliance for Rare Diseases
+32 475 61 57 11 (Brussels, Belgium)
Erik.Tambuyzer@biopontisalliance.org

Richard Basile, CEO BioPontis Alliance for Rare Diseases
+1 919 345 5386 (Raleigh, USA)
Richard.Basile@biopontisalliance.org